Nuvama cuts target price on Alkem Lab: Find out why?

Nuvama Institutional Equities cut the target price on Alkem Laboratories by 3.5% to Rs 5,840 from Rs 6,053 as the brokerage house sees a slowdown in acute business. It retained its ‘Hold’ call on the stock. It also slashed the earnings per share estimates by 3% for FY26 and 2% for FY27. It further cut the return on equity estimate to 17% in FY27. 

The brokerage firm said that the company’s domestic business declined sequentially, which reflects a slowdown in the acute business. Adding, the impact of no price hike in the NLEM portfolio, which makes up 30% of domestic revenue. 

Alkem Laboratories’ domestic business in the third quarter of the current fiscal year dropped 4% sequentially to Rs 2,400 crore. However, it grew 6% year-on-year. The domestic business missed Nuvama’s estimates. 

Also Read HDFC AMC shares jump 5%. Here are 4 reasons why brokerages are bullish Nomura maintains Buy on ITC. Here are 3 reasons why… ‘US to deport 7.25 lakh Indians’, Rajiv Shukla shares key data, ‘they were earning good, suddenly turned…’ Why is the stock market falling today? Here are 3 reasons…

Not just domestic business, but international business also faced some heat. The US exports contracted 7% YoY while the international exports contracted 14% YoY. However, the brokerage firm thinks that it may return to normal levels with growth in the domestic acute and US generics. 

“We note Alkem’s gross margin in 9MFY25 is attractive; however, this may not sustain in FY26E with growth in domestic acute and US generics business. We think cost optimisation is necessary to expand EBITDA margin,” said Nuvama in a research note. 

Further, it said that acquisitions have a small quantum as the company recently acquired Bombay Ortho and Adroit Biomed, which made a combined revenue of Rs 60 crore for FY24, 0.5% of consolidated revenue. “We note, that under new management, Alkem is making some hard decisions (divestment/M&A), even though the quantum is very small for now,” Nuvama said. 

Alkem Laboratories in Q3

The company’s consolidated net profit rose 6% YoY to Rs 641 crore from Rs 604 crore in Q3 FY24. Sequentially, profit fell almost 9% from 702 crore in the previous quarter of the same financial year. Its total income for the quarter stood at Rs 3,467 crore,

 » Read More

Related Articles

Senior Citizen Fixed Deposits offering highest interest rates in March 2025 – Compare rates

Fixed deposits (FDs) have been a go-to investment choice in India for quite some time, particularly among senior citizens who prioritize financial stability and a consistent income. To meet the needs of this age group, Senior Citizen FDs provide better interest rates along with a range of other benefits. Before you jump into these investment

Mcap of five of top-10 most valued firms declines Rs 93,000 crore; Infosys, TCS hit hard

The combined market capitalisation of five of the top-10 most valued firms declined by Rs 93,357.52 crore, with IT giants Infosys and Tata Consultancy Services taking the biggest hit, in line with a weak trend in domestic equities. Last week, the BSE Sensex benchmark declined 503.67 points or 0.68 per cent, and the NSE Nifty

US Fed interest rate decision, tariff-related developments to drive mkt movement this week: Analysts

The US Fed interest rate decision, global trends, tariff-related developments and trading activity of foreign investors will drive the equity market movement this week, analysts said. Among macroeconomic data announcement, WPI inflation for February is scheduled to be announced on Monday. “Persistent uncertainties surrounding global trade and the fear of a US recession may continue

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Senior Citizen Fixed Deposits offering highest interest rates in March 2025 – Compare rates

Fixed deposits (FDs) have been a go-to investment choice in India for quite some time, particularly among senior citizens who prioritize financial stability and a consistent income. To meet the needs of this age group, Senior Citizen FDs provide better interest rates along with a range of other benefits. Before you jump into these investment

Mcap of five of top-10 most valued firms declines Rs 93,000 crore; Infosys, TCS hit hard

The combined market capitalisation of five of the top-10 most valued firms declined by Rs 93,357.52 crore, with IT giants Infosys and Tata Consultancy Services taking the biggest hit, in line with a weak trend in domestic equities. Last week, the BSE Sensex benchmark declined 503.67 points or 0.68 per cent, and the NSE Nifty

US Fed interest rate decision, tariff-related developments to drive mkt movement this week: Analysts

The US Fed interest rate decision, global trends, tariff-related developments and trading activity of foreign investors will drive the equity market movement this week, analysts said. Among macroeconomic data announcement, WPI inflation for February is scheduled to be announced on Monday. “Persistent uncertainties surrounding global trade and the fear of a US recession may continue

Flexi cap funds vs Multi cap funds: Which is an appropriate choice during volatile times

In September 2024, I wrote a piece, ‘Flexi Cap Funds v/s Multi Cap Funds: Which Is Better at a Market High?’. The valuations of the Indian equity market then were exceptionally high: the BSE SmallCap P/E and BSE MidCap P/E were at around 36x and 34x, respectively, while the BSE LargeCap Index was nearly 26x.

Top 10 mutual funds holding IndusInd Bank may take a Hit: Do you own these?

Indian banking has witnessed various challenges over the last few years, from mounting non-performing assets (NPAs) to regulatory action and issues of corporate governance. Banks are generally considered pillars of country’s financial stability, and thus any disruptions within prominent banks could have extensive ramifications. Institutional investors, regulators, and analysts are keenly watching such events because